Azole Antifungals (itraconazole, voriconazole, posaconazole) — Prior Authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements for azole antifungal agents (itraconazole, voriconazole, posaconazole and related formulations) for CareOregon members, including indication, specialist initiation, prior trial/contraindication logic, and liquid formulation criteria.
No material clinical or coverage changes in this revision.
Azole Antifungal Coverage Criteria
Itraconazole (including solution) — Initial Authorization
Covered when ALL of the following are met:
See Placement-Files: ICD-10-CM with decimal
Applies only to liquid dosage form
Voriconazole (including suspension) — Initial Authorization
Covered when ALL of the following are met:
Applies only to suspension formulation
Posaconazole (including suspension) — Initial Authorization
Covered when ALL of the following are met:
Noxafil PowderMix is nonformulary
Authorization durations
Approval duration rules:
Noxafil PowderMix is designated as nonformulary and therefore is not a covered product under this policy. If posaconazole is clinically indicated and a liquid formulation is required, prescribers must use an alternative posaconazole suspension that meets medical necessity criteria (for example: member ≤12 years old, treatment of current oropharyngeal candidiasis in members with HIV/AIDS, or inability to take solid oral medication).
Provider Requirements and Documentation
Prior authorization required; approval lengths
Prior authorization is required for itraconazole, voriconazole, and posaconazole. Approval length: for prophylaxis of fungal infections, approve for 6 months; for other FDA‑approved indications, approve for the treatment duration per the FDA indication or supported compendia.
- Prior authorization applies to listed azole antifungals.
- Prophylaxis approvals: 6 months.
- Other indications: duration per FDA indication or supported compendia.
Required trials and step-therapy logic
Step-therapy and trial logic require either failure of topical formulary antifungals or documentation that systemic therapy is needed. For systemic azoles, required prior trials differ by agent: itraconazole—trial or contraindication of terbinafine AND fluconazole; voriconazole and posaconazole—trial or contraindication of fluconazole and itraconazole (and for posaconazole, also voriconazole).
- Topical formulary agents (examples: miconazole, clotrimazole, ketoconazole) must be failed OR medical records must confirm systemic therapy is needed (chunk 6).
- Itraconazole requests require terbinafine AND fluconazole to be not indicated OR failed an adequate trial OR contraindicated (chunk 8).
- Voriconazole requires fluconazole and/or itraconazole to be not indicated, failed, or contraindicated per criteria (chunks 14,15).
- Posaconazole requires fluconazole, itraconazole, and voriconazole to be not indicated, failed, or contraindicated as applicable (chunks 17,18).
Clinical records and prior trial documentation
Submit medical records (for example, chart notes) that confirm the need for a systemic antifungal and document adequate trials or documented contraindications/inappropriateness of topical formulary agents and required oral agents (terbinafine, fluconazole, itraconazole, voriconazole) as applicable.
- Documentation must show failure of topical agents or justification that systemic therapy is required (chunk 6).
- Include records demonstrating trials at maximum tolerated dose or documentation of contraindication/inappropriateness for required comparators (chunks 8,14,17).
Map diagnosis to Oregon Prioritized List funding
Ensure the diagnosis is paired to the Oregon Prioritized List when applicable. Documentation must support that the diagnosis is above the funding line or that treating the condition improves a comorbid diagnosis that is above the funding line (use Placement‑Files: ICD‑10‑CM with decimal for pairing).
- If multiple placements exist, reviewer clinical judgment or applicable guideline notes determine the pairing (chunk 12).
- Covered = diagnosis above the funding line (lines 1–470); below line or not on list requires demonstration of improvement in a covered comorbid diagnosis (chunk 10).
Denial risk: indication and medical necessity not met
The request may be denied if the antifungal is not indicated or supported for the infection or prophylaxis, or if the requested service is not medically necessary. Medically necessary requires safe, effective use consistent with professional standards, use of the most cost‑effective service, prescribing within provider scope, and being necessary for participation in care, work, school, or social activities.
- Denial risk when indication for therapy or prophylaxis is not documented (chunk 5).
- Medical necessity includes consistency with guidelines, cost‑effectiveness, appropriate provider scope, and functional necessity (chunk 11).
Denial risk: missing prior trials or contraindication documentation
Requests may be denied when required prior trials or documented contraindications are not provided. Examples: itraconazole requests without documentation of trial/contraindication for terbinafine AND fluconazole; voriconazole/posaconazole requests without documentation of trial/contraindication for fluconazole and itraconazole (and voriconazole for posaconazole) as specified.
- Itraconazole: denial risk if terbinafine AND fluconazole have not been tried at adequate dose or contraindications are not documented (chunk 8).
- Voriconazole: denial risk if fluconazole and/or itraconazole trials or contraindications are not documented (chunks 14,15).
- Posaconazole: denial risk if fluconazole, itraconazole, and voriconazole trials or contraindications are not documented as required (chunks 17,18).
Background and Scope
This policy governs prior authorization for azole antifungal agents—specifically itraconazole, voriconazole, and posaconazole—for treatment and prophylaxis of fungal infections. It applies to all listed formulations including oral solids and liquid dosage forms, and sets requirements for indication support, specialist initiation where specified, documented trials of alternative antifungals or contraindications, and medical necessity criteria for liquid formulations. The policy references the Oregon Prioritized List when determining whether a diagnosis is fundable and specifies approval durations such as 6 months for prophylaxis.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.